Literature DB >> 26940073

Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy.

Francesco Piva1, Matteo Giulietti2, Matteo Santoni3, Giulia Occhipinti2, Marina Scarpelli4, Antonio Lopez-Beltran5, Liang Cheng6, Giovanni Principato2, Rodolfo Montironi4.   

Abstract

Epithelial-to-mesenchymal transition (EMT) is a developmentally vital reversible process by which fully differentiated cells lose their epithelial features and acquire a migratory mesenchymal phenotype. EMT contributes to the metastatic potential of tumors. The expression profile and other biological properties of EMT suggest potential targets for cancer therapy, including in renal-cell carcinoma (RCC). The preclinical and clinical results have substantiated the promises that dysregulated elements leading to EMT can be a potential target in RCC patients. In this study, we illustrated the pathogenic and prognostic role of EMT in RCC. In addition, we reconstructed, by literature analysis, the different pathways implicated in the EMT process, thus supporting the rational for future EMT-directed therapeutic approaches for RCC patients.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26940073     DOI： 10.1007/s40291-016-0192-5

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN： 1177-1062            Impact factor:   4.074


  46 in total

1.  Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.

Authors:  Hans J Hammers; Henk M Verheul; Brenda Salumbides; Rajni Sharma; Michelle Rudek; Janneke Jaspers; Preeti Shah; Leigh Ellis; Li Shen; Silvia Paesante; Karl Dykema; Kyle Furge; Bin T Teh; George Netto; Roberto Pili
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

2.  Expression of Snail and Slug in renal cell carcinoma: E-cadherin repressor Snail is associated with cancer invasion and prognosis.

Authors:  Shuji Mikami; Ken-Ichi Katsube; Mototsugu Oya; Masaru Ishida; Takeo Kosaka; Ryuichi Mizuno; Makio Mukai; Yasunori Okada
Journal:  Lab Invest       Date:  2011-08-01       Impact factor: 5.662

Review 3.  Epithelial-to-mesenchymal transition in renal neoplasms.

Authors:  Huiying He; Cristina Magi-Galluzzi
Journal:  Adv Anat Pathol       Date:  2014-05       Impact factor: 3.875

Review 4.  Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.

Authors:  Roberto Iacovelli; Daniele Alesini; Antonella Palazzo; Patrizia Trenta; Matteo Santoni; Laura De Marchis; Stefano Cascinu; Giuseppe Naso; Enrico Cortesi
Journal:  Cancer Treat Rev       Date:  2013-09-11       Impact factor: 12.111

5.  SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5'-CACCT sequences in candidate target genes.

Authors:  K Verschueren; J E Remacle; C Collart; H Kraft; B S Baker; P Tylzanowski; L Nelles; G Wuytens; M T Su; R Bodmer; J C Smith; D Huylebroeck
Journal:  J Biol Chem       Date:  1999-07-16       Impact factor: 5.157

Review 6.  Integrin-linked kinase: a cancer therapeutic target unique among its ILK.

Authors:  Gregory Hannigan; Armelle A Troussard; Shoukat Dedhar
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

7.  MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway.

Authors:  Takeshi Yamasaki; Naohiko Seki; Hirofumi Yoshino; Toshihiko Itesako; Hideo Hidaka; Yasutoshi Yamada; Shuichi Tatarano; Tomokazu Yonezawa; Takashi Kinoshita; Masayuki Nakagawa; Hideki Enokida
Journal:  J Urol       Date:  2013-02-27       Impact factor: 7.450

8.  NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.

Authors:  Allan J Pantuck; Jiabin An; Huiren Liu; Matthew B Rettig
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

9.  Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma.

Authors:  Hirofumi Yoshino; Hideki Enokida; Toshihiko Itesako; Shuichi Tatarano; Takashi Kinoshita; Miki Fuse; Satoko Kojima; Masayuki Nakagawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2013-05-02       Impact factor: 3.172

10.  Protein expression of ZEB2 in renal cell carcinoma and its prognostic significance in patient survival.

Authors:  Yong Fang; Jinhuan Wei; Jiazheng Cao; Hongwei Zhao; Bing Liao; Shaopeng Qiu; Daohu Wang; Junhang Luo; Wei Chen
Journal:  PLoS One       Date:  2013-05-02       Impact factor: 3.240
View more
  27 in total

1.  Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development.

Authors:  Matteo Giulietti; Giulia Occhipinti; Giovanni Principato; Francesco Piva
Journal:  Cell Oncol (Dordr)       Date:  2016-05-30       Impact factor: 6.730

2.  Liquid biopsies in renal cell carcinoma with focus on epigenome analysis.

Authors:  Alessia Cimadamore; Matteo Santoni; Francesco Massari; Liang Cheng; Antonio Lopez-Beltran; Marina Scarpelli; Rodolfo Montironi
Journal:  Ann Transl Med       Date:  2019-09

Review 3.  Molecular mechanisms underlying the antimetastatic activity of bufalin.

Authors:  Jie Wang; Yue Xia; Qingshong Zuo; Teng Chen
Journal:  Mol Clin Oncol       Date:  2018-03-21

4.  Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.

Authors:  M Giulietti; G Occhipinti; G Principato; F Piva
Journal:  Cell Oncol (Dordr)       Date:  2017-02-15       Impact factor: 6.730

5.  Canadian Urological Association guideline: Management of small renal masses - Full-text.

Authors:  Patrick O Richard; Philippe D Violette; Bimal Bhindi; Rodney H Breau; Wassim Kassouf; Luke T Lavallée; Michael Jewett; John R Kachura; Anil Kapoor; Maxine Noel-Lamy; Michael Ordon; Stephen E Pautler; Frédéric Pouliot; Alan I So; Ricardo A Rendon; Simon Tanguay; Christine Collins; Maryam Kandi; Bobby Shayegan; Andrew Weller; Antonio Finelli; Andrea Kokorovic; Jay Nayak
Journal:  Can Urol Assoc J       Date:  2022-02       Impact factor: 1.862

6.  Downregulation of Crystallin Lambda 1 is a New Independent Prognostic Marker in Clear Cell Renal Cell Carcinoma.

Authors:  Lingsong Feng; Guodong Ding; Yang Zhou; Haiyuan Zhu; Huiming Jiang
Journal:  Pharmgenomics Pers Med       Date:  2022-10-10

7.  Association of Expression Levels or Activation Status of STAT3 with Treatment Outcomes of Sunitinib in Patients with Renal Cell Carcinoma.

Authors:  Kazuhiro Yamamoto; Takuto Hara; Tsutomu Nakagawa; Midori Hirai; Hideaki Miyake; Masato Fujisawa; Ikuko Yano
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

8.  The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases.

Authors:  Peio Errarte; Rosa Guarch; Rafael Pulido; Lorena Blanco; Caroline E Nunes-Xavier; Maider Beitia; Javier Gil; Javier C Angulo; José I López; Gorka Larrinaga
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

9.  Overexpression of CAPN2 promotes cell metastasis and proliferation via AKT/mTOR signaling in renal cell carcinoma.

Authors:  Chenkui Miao; Chao Liang; Ye Tian; Aiming Xu; Jundong Zhu; Kai Zhao; Jianzhong Zhang; Yibo Hua; Shouyong Liu; Huiyu Dong; Chao Zhang; Shifeng Su; Pu Li; Chao Qin; Zengjun Wang
Journal:  Oncotarget       Date:  2017-10-26

Review 10.  The Pathology and Molecular Genetics of Sarcomatoid Renal Cell Carcinoma: A Mini-Review.

Authors:  Shuanzeng Wei; Tahseen Al-Saleem
Journal:  J Kidney Cancer VHL       Date:  2017-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.